IRBM accelerates the discovery and preclinical development of small molecule, peptide and antibody drug candidates. Previously a Merck Research Labs site, IRBM retains the core scientific team that developed four drugs currently on the market.
Our integrated and stand alone platform capabilities include assay development, high-throughput screening and hit ID, medicinal and peptide chemistry, structural biology, DMPK and custom biomarker services to deliver a candidate ready for IND enabling studies. We have a proprietary compound collection for screening purposes, a NMR facility, and a phage display library as well.
The core team has extensive experience in the drug discovery and development approach undertaken by large and small companies, and are experts in small molecule and peptide therapeutics. The IRBM team has delivered over 25 preclinical candidates in 9 years, published more than 800 papers and been issued more than 100 patents.
IRBM offers integrated drug discovery and development services, starting with validated targets and ending with the delivery of a preclinical candidate ready for tox screening. Alternately, any subset of phases in this process can be performed individually.
IRBM's scientific team has developed or contributed to five marketed drugs, and due to the company's legacy as an ex-Merck Research Laboratories site, the scientific team is highly professional and experienced. The team provides this scientific know-how as part of IRBM's integrated drug discovery services.
IRBM provides NMR-mediated metabolomics capabilities in biofluids. The use of the NMR platform ensures that large studies can be performed at a low cost, and that studies can be unbiased. NMR provides a small drop in sensitivity compared to the more expensive mass spectrometry.
Structural biology capabilities, including NMR, are available through IRBM's scientific teams.
IRBM counts over 50 medicinal chemists, many of whom have been involved in the development of 5 drugs currently on the market. IRBM's medicinal chemists are highly skilled in small molecule discovery and development, and have often been capable of overcoming challenges brought to IRBM by their customers.
The leaders of the Medicinal Chemistry unit and of the Chemistry department have been named Heroes of Chemistry 2017 by the American Chemical Society.
IRBM's dedicated pharmacology unit provides in vitro DMPK capabilities as well as more specialized assays such as an in vitro blood-brain barrier penetration assay. In vivo pharmacology capabilities are also available.
IRBM has a proprietary M13 phage display library codifying for either linear or loop-constrained dodecamers, and the library undergoes continuous expansion into other -mers as well. The phage display library can be screened on a client's behalf, and IRBM offers development capabilities downstream of these results.
IRBM's 600-MHz NMR facility hosts four machines which are used for structural biology, protein-ligand interaction studies, 3D structure determination, compound stability testing, and metabolomics. The NMR facility accepts individual projects and supports IRBM's larger integrated drug discovery capabilities.
Our Screening Technologies unit supports assay development for screening campaigns, and provides hit ID services either as standalone services, or as part of an integrated drug discovery program. Fully automated and with access to a proprietary, curated compound collection, our team will work with you to ensure the highest-quality hits can be identified.
IRBM S.p.A. has not received any reviews.
IRBM S.p.A. has not received any endorsements.